v3.26.3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Class A Shares
Class B Shares
Common Stock
Class A Shares
Common Stock
Class B Shares
Additional Paid-in capital
Retained Earnings
Non-Controlling Interests
Beginning Balance (in shares) at Dec. 31, 2024       9,200,000,000 54,087,158,000      
Beginning Balance at Dec. 31, 2024 $ 149,976     $ 9 $ 54 $ 125,484 $ 17,124 $ 7,305
Contributions 135             135
Distributions (135)             (135)
Net income attributable to Guardian Pharmacy Services, Inc. 9,448           9,448  
Net income (loss) attributable to non-controlling interest (175)             (175)
Share-based compensation forfeitures (in shares)         (516,000)      
Share-based compensation forfeitures (1)         (1)    
Share-based compensation expense 3,969         3,969    
Conversion of Class B common stock to Class A common stock (in shares)       13,519,946,000 (13,519,946,000)      
Conversion of Class B common stock to Class A common stock       $ 14 $ (14)      
Ending Balance (in shares) at Mar. 31, 2025       22,719,946,000 40,566,696,000      
Ending Balance at Mar. 31, 2025 163,217     $ 23 $ 40 129,452 26,572 7,130
Beginning Balance (in shares) at Dec. 31, 2024       9,200,000,000 54,087,158,000      
Beginning Balance at Dec. 31, 2024 149,976     $ 9 $ 54 125,484 17,124 7,305
Net income attributable to Guardian Pharmacy Services, Inc. 28,296 $ 8,413 $ 19,883          
Net income (loss) attributable to non-controlling interest (603)              
Ending Balance (in shares) at Sep. 30, 2025       36,253,744,000 27,066,890,000      
Ending Balance at Sep. 30, 2025 195,497     $ 36 $ 27 138,273 45,420 11,741
Beginning Balance (in shares) at Mar. 31, 2025       22,719,946,000 40,566,696,000      
Beginning Balance at Mar. 31, 2025 163,217     $ 23 $ 40 129,452 26,572 7,130
Contributions 1,094             1,094
Non-cash equity contribution 2,141             2,141
Distributions (54)             (54)
Net income attributable to Guardian Pharmacy Services, Inc. 9,030           9,030  
Net income (loss) attributable to non-controlling interest (203)             (203)
Share-based compensation forfeitures (in shares)       (68,000) (202,000)      
Share-based compensation forfeitures (1)         (1)    
Share-based compensation expense 4,447         4,447    
Issuance of Class A common stock associated with vested restricted stock units (in shares)       10,713,000        
Ending Balance (in shares) at Jun. 30, 2025       22,730,591,000 40,566,494,000      
Ending Balance at Jun. 30, 2025 179,671     $ 23 $ 40 133,898 35,602 10,108
Contributions 390             390
Non-cash equity contribution 1,468             1,468
Distributions (422)         (422)    
Net income attributable to Guardian Pharmacy Services, Inc. 9,818 3,638 6,180       9,818  
Net income (loss) attributable to non-controlling interest (225)             (225)
Share-based compensation forfeitures (in shares)       (132,000) (394,000)      
Share-based compensation forfeitures (17)         (17)    
Share-based compensation expense 4,373         4,373    
Conversion of Class B common stock to Class A common stock (in shares)       13,523,285,000 (13,523,285,000)      
Conversion of Class B common stock to Class A common stock       $ 13 $ (13)      
Issuance of Class B common stock associated with acquisition (in shares)         24,075,000      
Issuance of Class B common stock associated with acquisition 441         441    
Ending Balance (in shares) at Sep. 30, 2025       36,253,744,000 27,066,890,000      
Ending Balance at Sep. 30, 2025 195,497     $ 36 $ 27 138,273 45,420 11,741
Beginning Balance (in shares) at Dec. 31, 2025       36,253,744 27,066,890      
Beginning Balance at Dec. 31, 2025 217,924     $ 36 $ 27 139,353 66,343 12,165
Contributions 79             79
Distributions (960)             (960)
Net income attributable to Guardian Pharmacy Services, Inc. 13,295           13,295  
Net income (loss) attributable to non-controlling interest 249             249
Share-based compensation forfeitures (47)         (47)    
Share-based compensation expense 1,794         1,794    
Conversion of Class B common stock to Class A common stock (in shares)       13,527,437 (13,527,437)      
Conversion of Class B common stock to Class A common stock 0     $ 14 $ (14)      
Other 90         90    
Ending Balance (in shares) at Mar. 31, 2026       49,781,181 13,539,453      
Ending Balance at Mar. 31, 2026 232,424     $ 50 $ 13 141,190 79,638 11,533
Beginning Balance (in shares) at Dec. 31, 2025       36,253,744 27,066,890      
Beginning Balance at Dec. 31, 2025 217,924     $ 36 $ 27 139,353 66,343 12,165
Net income attributable to Guardian Pharmacy Services, Inc. 53,847 38,836 15,011          
Net income (loss) attributable to non-controlling interest 938              
Ending Balance (in shares) at Sep. 30, 2026       63,320,300 22,004      
Ending Balance at Sep. 30, 2026 279,720     $ 63 $ 0 146,982 120,190 12,485
Beginning Balance (in shares) at Mar. 31, 2026       49,781,181 13,539,453      
Beginning Balance at Mar. 31, 2026 232,424     $ 50 $ 13 141,190 79,638 11,533
Contributions 574             574
Distributions (327)             (327)
Net income attributable to Guardian Pharmacy Services, Inc. 21,872           21,872  
Net income (loss) attributable to non-controlling interest 249             249
Share-based compensation forfeitures (48)         (48)    
Share-based compensation expense 2,898         2,898    
Issuance of Class A common stock associated with vested restricted stock units (in shares)       11,703        
Ending Balance (in shares) at Jun. 30, 2026       49,792,884 13,539,453      
Ending Balance at Jun. 30, 2026 257,642     $ 50 $ 13 144,040 101,510 12,029
Contributions 527             527
Distributions (511)             (511)
Net income attributable to Guardian Pharmacy Services, Inc. 18,680 $ 14,815 $ 3,865       18,680  
Net income (loss) attributable to non-controlling interest 440             440
Share-based compensation forfeitures (279)         (279)    
Share-based compensation expense 2,843         2,843    
Conversion of Class B common stock to Class A common stock (in shares)       13,527,416 (13,527,416)      
Conversion of Class B common stock to Class A common stock 0     $ 13 $ (13)      
Issuance of Class B common stock associated with acquisition (in shares)         9,967      
Issuance of Class B common stock associated with acquisition 378         378    
Ending Balance (in shares) at Sep. 30, 2026       63,320,300 22,004      
Ending Balance at Sep. 30, 2026 $ 279,720     $ 63 $ 0 $ 146,982 $ 120,190 $ 12,485